πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11974980

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pe

Provectus Pharmatech, Inc. Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11970543

Anti-CD39 antibodies and use thereof

Arcus Biosciences, Inc. Β· Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11965032

Anti-CD20 antibody compositions

TG Therapeutics, Inc. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11964985

Anti-cancer compounds targeting Ral GTPases and methods of using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11958901

Anti-CXCR5 antibodies and compositions and uses thereof

The Regents of the University of California Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11958894

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11952365

Anti-viral compounds

Aligos Therapeutics, Inc. Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11951131

Anti-SLAMF7 chimeric antigen receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11952427

Anti-CD40 antibodies and uses thereof

CytomX Therapeutics, Inc. Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11945824

Heterocyclic compounds as anti-viral agents

Enanta Pharmaceuticals, Inc. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11945872

Anti-ACVR1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944644

T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938226

Abiotic anti-VEGF nanoparticle

The Regents of the University of California Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938192

Dosage regimes for the administration of an anti-CD19 ADC

ADC THERAPEUTICS SA Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11932703

Anti-ROR1 antibody and ROR1-targeting engineered cells

Caribou Biosciences, Inc. Β· Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11932698

Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof

Nanjing Legend Biotech Co., Ltd Β· Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11932606

Anti-cancer/anti-fibrosis compounds

The Regents of the University of California Β· Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11926668

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11925685

DNA antibody constructs encoding anti-ZIKV envelope antibodies

Inovio Pharmaceuticals, Inc. Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11926670

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11919965

Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11918640

Methods of preparing anti-human papillomavirus antigen T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11912762

Method of treating osteoarthritis by administering an anti-connexin 43 antibody

The Board of Regents of the University of Texas System Β· Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11911464

Anti-parasitic immunological compositions

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted